Clinical Study

A041501- A Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All

Posted Date: Jan 18, 2021

  • Investigator: Emily Curran
  • Specialties: Cancer, Leukemia, Oncology
  • Type of Study: Drug

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. The primary outcome measured will be event free survival.


To Be Eligible: Must Have New Diagnosis Of Cd-22 Positive B-Cell Acute Lymphoblastic Leukemia, Ecog 0-2, Adequate Organ Function, No Prior Therapy For Acute Leukemia Except Emergency Therapy, No Ascites, Effusions Or Significant Edema, No Patients With Down Syndrome


Acute Lymphoblastic Leukemia, Leukemia, Hematology

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.